Champions Oncology
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 210
- Market Cap
- -
- Introduction
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Champions Oncology
- Target Recruit Count
- 17
- Registration Number
- NCT02720796
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
News
Champions Oncology Appoints Rob Brainin as New CEO to Drive Data Platform Expansion
Champions Oncology has appointed Rob Brainin as Chief Executive Officer effective August 25, 2025, succeeding Dr. Ronnie Morris who will transition to Executive Chair.
Champions Oncology Launches Comprehensive Radiopharmaceutical Services Platform with Expanded Isotope Capabilities
Champions Oncology has launched a fully integrated radiopharmaceutical services platform combining advanced radiochemistry infrastructure with their extensive patient-derived xenograft tumor model bank.
Turbine Unveils First-Ever Virtual Lab Platform for Cell Simulations in Drug Development
Turbine has launched the world's first virtual lab using cell simulations, aligning with FDA's recent move to phase out animal testing requirements in drug development.